S-edelfosine (S-CP201) / RDP Pharma - LARVOL DELTA

Phosphatidylcholine and CHPT1 as Central Drivers of Chemoresistance in Colorectal Cancer: Lipidomic and Functional Insights. (PubMed, Cells) - "Notably, edelfosine-mediated disruption of the Kennedy pathway enhances chemosensitivity in the resistant CRC model. Collectively, our study identifies CHPT1 and PC metabolism as central determinants of CRC drug response and proposes edelfosine-based metabolic reprogramming as a promising strategy to overcome resistance."

Journal • Colorectal Cancer • Oncology • Solid Tumor

Efficacy and tolerability of a enantiomer of Edelfosine (S-CP201) in pancreatic cancer PDX models as a single agent and in combination with approved drugs in clinical use (AACR 2025) - "Treatment groups included S-CP201, R-CP201 (20 mg/kg p.o. each; given for 5 days/week over 3 w.), Gemcitabine (Gem.; ) (50 mg/kg i.p., 3 d./w. and/or albumin-bound Paclitaxel in pancreatic adenocarcinoma, including in patients with tumors containing mutated Ras. An IND enabling data package is underway."

Clinical • Combination therapy • Genito-urinary Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Prostate Cancer • Solid Tumor • FAS

Non-clinical toxicity studies of S-CP201 (AACR 2025) - "An in vitro hemolysis test (up to 20 µM) was negative for S-CP201. Overall, this S-CP201 non-clinical safety package supports proceeding to Phase 1 studies."

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FAS

Improved pharmacokinetic properties of the purified S-enantiomer of the alkylphospholipid Edelfosine compared to the racemic mixture: Potential orally available novel anticancer agent active against pancreatic cancer (AACR 2025) - "No major toxicity was detected for S-CP201 in rats and mice. These results confirm PK and PD advantages and acceptable tolerability of S-CP201 and support its further development as an anticancer agent is warranted."

PK/PD data • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor • FAS